Optimizing the use of carbapenems in the face of increasing Gram-negative resistance

Critical Care

Volumn 12, Issue SUPPL. 4, 2008, Pages

  Ramphal, Reuben ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; EDITORIAL; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; MULTIDRUG RESISTANCE;

CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 45949086909     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6817     Document Type: Editorial

References (4)

1. Slama TG Gram-negative antibiotic resistance: There is a price to pay Crit Care 2008, 12(Suppl 4):S4.
2. Owens RC Jr An overview of harms associated with β-lactam antimicrobials: Where do the carbapenems fit in? Crit Care 2008, 12(Suppl 4):S3.
3. Rahal JJ The role of carbapenems in initial therapy for serious Gram-negative infections Crit Care 2008, 12(Suppl 4):S5.
4. Nicolau DP Pharmacodynamic optimization of β-lactams in the patient care setting Crit Care 2008, 12(Suppl 4):S2.